Trials that use: Interim analysis / alpha spending
New to this method? Read the tutorial →
11,819 results
- Oxidative Stress in Asthma: Complete Statistical AnalysisIndependent statistical analysis of Oxidative Stress in Asthma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04512547).
- OXN PR Tablet 5/2.5 mg and20/10 mg PK Study in Chinese Moderate to Severe Chronic Non-malignant Patients: Complete Statistical AnalysisIndependent statistical analysis of OXN PR Tablet 5/2.5 mg and20/10 mg PK Study in Chinese Moderate to Severe Chronic Non-malignant Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- OXY-RIndependent statistical analysis of Intranasal Oxytocin for the Treatment of Children and Adolescents With Autism Spectrum Disorders (ASD): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Oxygen Monitoring of Patients After Surgery on the Hospital General Care Floor: Complete Statistical AnalysisIndependent statistical analysis of Oxygen Monitoring of Patients After Surgery on the Hospital General Care Floor: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Oxygen Reserve Index: Utility as Early Warning for Desaturation in Morbidly Obese Patients: Complete Statistical AnalysisIndependent statistical analysis of Oxygen Reserve Index: Utility as Early Warning for Desaturation in Morbidly Obese Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Oxytocin and CBSST for People With Schizophrenia: Complete Statistical AnalysisIndependent statistical analysis of Oxytocin and CBSST for People With Schizophrenia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01752712).
- Oxytocin Effects on Cardiac Electrophysiology: Complete Statistical AnalysisIndependent statistical analysis of Oxytocin Effects on Cardiac Electrophysiology: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01780337).
- Oxytocin Suppresses Substance Use Disorders Associated With Chronic Stress: Complete Statistical AnalysisIndependent statistical analysis of Oxytocin Suppresses Substance Use Disorders Associated With Chronic Stress: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02058251).
- OZGAMIndependent statistical analysis of Effectiveness of OZ439 as a Gametocytocidal and Transmission Blocking Agent: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02431650).
- P1A3BIndependent statistical analysis of Characterization of Brachial Arterial t-PA Release, Endothelial Function, Obesity and Inflammation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- P2PIndependent statistical analysis of CPAP vs ASV for Insomnia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02365064).
- P3: Pacemaker Patient Profiling Study: Complete Statistical AnalysisIndependent statistical analysis of P3: Pacemaker Patient Profiling Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00294060).
- PA-824-CL-007: Phase IIa Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis: Complete Statistical AnalysisIndependent statistical analysis of PA-824-CL-007: Phase IIa Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- PA21Independent statistical analysis of Study of Phosphate Levels in Patients With Chronic Kidney Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00824460).
- PABCIndependent statistical analysis of Physical Activity Behavior Change for Older Adults After Dysvascular Amputation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02738086).
- PACBACKIndependent statistical analysis of Spinal Manipulation and Patient Self-Management for Preventing Acute to Chronic Back Pain: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- PACEIndependent statistical analysis of Patients With Intermittent Claudication Injected With ALDH Bright Cells: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01774097).
- PACEIndependent statistical analysis of Physical Activity Choices Everyday: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03824769).
- PACE-RBBBIndependent statistical analysis of Pacing Affects Cardiovascular Endpoints in Patients With Right Bundle-Branch Block (The PACE-RBBB Trial): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- PACIFICIndependent statistical analysis of A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with…
- PACIFIC-5Independent statistical analysis of A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- PACIFIC-AFIndependent statistical analysis of Study to Gather Information About the Proper Dosing of the Oral FXIa Inhibitor BAY 2433334 and to Compare the Safety of the Study Drug to Apixaban, a Non-vitamin…
- PACIFIC-AMIIndependent statistical analysis of Study to Gather Information About the Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following an Acute Heart Attack: primary endpoint results, effect…
- PACK-PMIndependent statistical analysis of Animal Assisted Intervention With Dogs for Children With ADHD: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05102344).
- Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01796197).
- Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size…
- Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine Cancer: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Paclitaxel and Carboplatin or Temozolomide in Treating Patients With Stage IV Melanoma: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel and Carboplatin or Temozolomide in Treating Patients With Stage IV Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer: primary endpoint results, effect estimate with confidence…
- Paclitaxel, Bevacizumab and Pemetrexed in Patients With Untreated, Advanced Non-Small Cell Lung Cancer Using Web-Based Data Collection, Patient Self-Reporting of Adverse Effects and Automated Response Assessment: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel, Bevacizumab and Pemetrexed in Patients With Untreated, Advanced Non-Small Cell Lung Cancer Using Web-Based Data Collection, Patient Self-Reporting of Adverse Effects and Automated Response Assessment: primary endpoint…
- Paclitaxel, Carboplatin, and Panitumumab in Treating Patients With Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel, Carboplatin, and Panitumumab in Treating Patients With Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women): Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04209686).
- Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer: primary endpoint results, effect estimate with…
- Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN): Complete Statistical AnalysisIndependent statistical analysis of Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02410551).
- Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS): Complete Statistical AnalysisIndependent statistical analysis of Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02469415).
- PACSIndependent statistical analysis of Cranberry for UTI Prevention in Residents of Long Term Care Facilities: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- PACU TelemedIndependent statistical analysis of Telemedicine Control Tower for the Post-Anesthesia Care Unit: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04020887).
- PADIndependent statistical analysis of Improvement In Scratch Behavior And Sleep In Patients With Atopic Dermatitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- PADD-ONIndependent statistical analysis of Peg-interferon ADDed to an Ongoing Nucleos(t)Ide Based Treatment in Patients With Chronic Hepatitis B to Induce Decrease of HBs-Antigen: primary endpoint results, effect estimate with confidence interval, sample-size…
- PAGE-1_AG1Independent statistical analysis of Pharmacogenomics for Antidepressant Guidance and Education 1 (PAGE-1_AG1): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01426516).
- PAHIndependent statistical analysis of Fluoxetine in Pulmonary Arterial Hypertension (PAH) Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03638908).
- PAI vs FNBIndependent statistical analysis of Analgesia After Total Knee Arthroplasty: Peri-Articular Injection Versus Epidural + Femoral Nerve Blockade: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Pain Control Following Sinus Surgery: Complete Statistical AnalysisIndependent statistical analysis of Pain Control Following Sinus Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03783702).
- Pain Expectations in Subjects With Osteoarthritis: Complete Statistical AnalysisIndependent statistical analysis of Pain Expectations in Subjects With Osteoarthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02155257).
- Pain in Traumatic Brain Injury – Basile, MD: Complete Statistical AnalysisIndependent statistical analysis of Pain in Traumatic Brain Injury - Basile, MD: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01136486).
- Pain Outcomes Following Intralesional Corticosteroid Injections: Complete Statistical AnalysisIndependent statistical analysis of Pain Outcomes Following Intralesional Corticosteroid Injections: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03630198).